PCM
IRWD icon

Prelude Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Prelude Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-112,475
Closed -$1.41M – 1612
2017
Q4 		$1.41M Buy
+112,475
New +$1.47M 0.11% 186

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Prelude Capital Management's IRWD Position: Q2 2026 in Review

Prelude Capital Management opened a new position in Ironwood Pharmaceuticals (IRWD) in Q2 2026: 18,400 shares worth $77.5K. The stake represents 0.01% of the portfolio and ranks #1140 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in IRWD as recently as Q4 2025.

Prelude Capital Management first reported a position in IRWD in Q3 2016 and has held it in 16 quarters since. The position peaked at $1.65M in Q2 2021. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Prelude Capital Management held 18,400 shares of Ironwood Pharmaceuticals worth $77.5K as of Q2 2026.
  • Ironwood Pharmaceuticals was a new Prelude Capital Management position in Q2 2026.
  • Ironwood Pharmaceuticals made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1140 holding.
  • Prelude Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2016 and has held it in 16 quarters since.
  • Prelude Capital Management's Ironwood Pharmaceuticals position peaked at $1.65M in Q2 2021.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.